These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 24794503)
1. Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis. Fissolo N; Cantó E; Vidal-Jordana A; Castilló J; Montalban X; Comabella M J Neuroimmunol; 2014 Jun; 271(1-2):56-9. PubMed ID: 24794503 [TBL] [Abstract][Full Text] [Related]
2. Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. Comabella M; Julià E; Tintoré M; Brieva L; Téllez N; Río J; López C; Rovira A; Montalban X J Neurol; 2008 Aug; 255(8):1136-41. PubMed ID: 18484235 [TBL] [Abstract][Full Text] [Related]
3. Relationship between the tumor necrosis factor receptor II (TNF-RII) gene polymorphism and sTNF-RII plasma levels in healthy controls and in rheumatoid arthritis. Tolusso B; Sacco S; Gremese E; La Torre G; Tomietto P; Ferraccioli GF Hum Immunol; 2004 Dec; 65(12):1420-6. PubMed ID: 15603867 [TBL] [Abstract][Full Text] [Related]
4. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Spoettl T; Hausmann M; Klebl F; Dirmeier A; Klump B; Hoffmann J; Herfarth H; Timmer A; Rogler G Inflamm Bowel Dis; 2007 Jun; 13(6):727-32. PubMed ID: 17260368 [TBL] [Abstract][Full Text] [Related]
5. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Glossop JR; Dawes PT; Nixon NB; Mattey DL Arthritis Res Ther; 2005; 7(6):R1227-34. PubMed ID: 16277675 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a. Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303 [TBL] [Abstract][Full Text] [Related]
7. [Serum levels and urinary excretion of soluble receptors for tumor necrosis factor (sTNF R) in patients with primary glomerulonephritis]. Kacprzyk F Pol Arch Med Wewn; 2002 Mar; 107(3):215-21. PubMed ID: 12107979 [TBL] [Abstract][Full Text] [Related]
9. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655 [TBL] [Abstract][Full Text] [Related]
10. Soluble cytokine receptors in renal vasculitis and lupus nephritis. Tesar V; Jirsa M; Zima T; Kalousová M; Bartunková J; Stejskalová A; Dostál C; Zabka J Med Sci Monit; 2002 Jan; 8(1):BR24-9. PubMed ID: 11782670 [TBL] [Abstract][Full Text] [Related]
11. Effects of soluble TNF receptor II (sTNF-RII), IL-1 receptor antagonist (IL-1ra), tumor load and hypermetabolism on malnutrition in children with acute leukemia. Schmid I; Schmitt M; Streiter M; Meilbeck R; Haas RJ; Stachel DK Eur J Med Res; 2005 Nov; 10(11):457-61. PubMed ID: 16354598 [TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of circulating levels of tumor necrosis factor receptor II and their association with TNF-RII gene polymorphisms. Vistoropsky Y; Ermakov S; Toliat MR; Trofimov S; Altmüller J; Malkin I; Nürnberg P; Livshits G Cytokine; 2010 Jul; 51(1):28-34. PubMed ID: 20488723 [TBL] [Abstract][Full Text] [Related]
13. [Soluble cytokinin receptors in renal vasculitis and lupus nephritis]. Tesar V; Jirsa M; Masek Z; Bartůnková J; Stejskalová A; Dostál C; Zabka J; Chábová V; Rysavá R Cas Lek Cesk; 1998 May; 137(9):271-5. PubMed ID: 9650355 [TBL] [Abstract][Full Text] [Related]
14. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657 [TBL] [Abstract][Full Text] [Related]
15. Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients. Jabłońska E; Pietruska Z Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):449-53. PubMed ID: 9437501 [TBL] [Abstract][Full Text] [Related]
16. Cytokine profile, Foxp3 and nuclear factor-kB ligand levels in multiple sclerosis subtypes. Alatab S; Maghbooli Z; Hossein-Nezhad A; Khosrofar M; Mokhtari F Minerva Med; 2011 Dec; 102(6):461-8. PubMed ID: 22193377 [TBL] [Abstract][Full Text] [Related]
17. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691 [TBL] [Abstract][Full Text] [Related]
18. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Sternberg Z; Weinstock-Guttman B; Hojnacki D; Zamboni P; Zivadinov R; Chadha K; Lieberman A; Kazim L; Drake A; Rocco P; Grazioli E; Munschauer F Mult Scler; 2008 Jul; 14(6):759-63. PubMed ID: 18505774 [TBL] [Abstract][Full Text] [Related]
19. Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability. Kallaur AP; Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Lopes J; de Carvalho Jennings Pereira WL; de Meleck Proença C; Borelli SD; Kaimen-Maciel DR; Maes M; Reiche EMV Mol Neurobiol; 2017 May; 54(4):2950-2960. PubMed ID: 27023227 [TBL] [Abstract][Full Text] [Related]
20. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Cantó E; Reverter F; Morcillo-Suárez C; Matesanz F; Fernández O; Izquierdo G; Vandenbroeck K; Rodríguez-Antigüedad A; Urcelay E; Arroyo R; Otaegui D; Olascoaga J; Saiz A; Navarro A; Sanchez A; Domínguez C; Caminero A; Horga A; Tintoré M; Montalban X; Comabella M Mult Scler; 2012 Jul; 18(7):983-90. PubMed ID: 22183936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]